Navigating the right path to better cancer targets.

CELLSELECT ^™

Significantly reduce the risk, time and cost associated with new target and drug discovery.

• Learn More:
• Identify novel targets
• Unique, advanced and compelling target validation data
• Determine and model clinical application of novel targets and treatments

Leading Cancer Research

BerGenBio's lead development program, BGB324, the first-in-class oral AXL inhibitor will enter Phase 1 clinical trials in 2012.

• Learn More:
  
• Our Approach to Oncology
  
• BGB324 – AXL inhibitor
  
• BerGenBio CRO Services

News

• 01.04.2012BerGenBio completes $9 million Series A financing for first in class oncology therapeutics
• 12.07.2011Promising prognostic and preclinical data for Acute Myeloid Leukemia and BerGenBio’s BGB324 at ASH
• 10.31.2011BerGenBio intitiates preclinical development of novel AXL inhibitor BGB324

View All News & Events

Events

• 14-16.09.2011 BerGenBio to Present at EPPC Toulouse